KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares Repurchased
Ratios

Sarepta Therapeutics (SRPT) Receivables - Net (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Receivables - Net data on record, last reported at $395.7 million in Q3 2025.

  • For Q3 2025, Receivables - Net fell 8.93% year-over-year to $395.7 million; the TTM value through Sep 2025 reached $395.7 million, down 8.93%, while the annual FY2024 figure was $602.0 million, 50.38% up from the prior year.
  • Receivables - Net reached $395.7 million in Q3 2025 per SRPT's latest filing, down from $527.3 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $659.4 million in Q1 2025 and bottomed at $118.2 million in Q1 2021.
  • Average Receivables - Net over 5 years is $309.7 million, with a median of $236.8 million recorded in 2023.
  • Peak YoY movement for Receivables - Net: skyrocketed 86.53% in 2023, then decreased 8.93% in 2025.
  • A 5-year view of Receivables - Net shows it stood at $153.0 million in 2021, then surged by 40.26% to $214.6 million in 2022, then surged by 86.53% to $400.3 million in 2023, then soared by 50.38% to $602.0 million in 2024, then plummeted by 34.27% to $395.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Net were $395.7 million in Q3 2025, $527.3 million in Q2 2025, and $659.4 million in Q1 2025.